论文部分内容阅读
我们用大剂量阿糖胞苷(Ara-C)对完全缓解(CR)后的成人急性髓细胞白血病(AML)住院患者进行早期巩固强化治疗,经1～5年随访观察,发现对延长患者生存期取得较好效果。现报道如下: 对象与方法 28例AML患者,均经化疗达CR,男性15例,女性13例,就诊时年龄22～52岁,中位年龄30.1岁,FAB分型:M_14例、M_26例、M_42例、M_310例,除M_3用全反式维甲酸达CR者外,其它类型均应用DA或HA方案达CR。6例未巩固强化治疗,8例应用DA和HA方案交替治疗,14例以大剂量Ara-C治疗。柔红霉素(D)每天40mg/m~2,
We used high-dose cytarabine (Ara-C) for the early consolidation and intensive treatment of acutely acute myeloid leukemia (AML) hospitalized patients after complete remission (CR). After 1 to 5 years of follow-up, we found that to extend the survival of patients. Achieve better results. Now reported as follows: Object and Methods 28 cases of AML patients were treated with chemotherapy CR, 15 males and 13 females, aged 22 to 52 years at the time of treatment, the median age of 30.1 years, FAB classification: M_14 cases, M_26 cases, M_42 cases, M_310 cases, except M_3 all-trans retinoic acid up to CR, other types are applied to DA or HA program up to CR. Six patients were not consolidated and intensive treatment was performed. Eight patients were treated alternately with DA and HA, and 14 patients were treated with large doses of Ara-C. Daunorubicin (D) 40 mg/m~2 daily